Group items matching

in title, tags, annotations or url

Aspire Pharma Limited has reaffirmed its commitment to combating prostate cancer by adding leuprorelin acetate as a branded generic to its oncology portfolio. This move solidifies Aspire's position as a leading specialty generics enterprise. Leuprorelin acetate is a hormone therapy recommended for patients with high-risk localized, locally advanced, and metastatic prostate cancer. It serves as an alternative to surgical castration for locally advanced cases. A pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen, providing a vital treatment option for patients.

Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its oncology portfolio. Leuprorelin acetate is hormone therapy recommended for patients with high-risk localised, locally advanced, and metastatic prostate cancer, serving as an alternative to surgical castration for locally advanced cases. Used as an alternative to surgical castration for locally advanced prostate cancer, a pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen. The British pharmaceutical company noted that one of its primary objectives is to seek "new investment opportunities" that brings products and companies into its portfolio, aligning closely with Aspire values and therapeutic focus areas. Prostate cancer is the most common cancer among men in the UK, with an average of over 52,000 men receiving a diagnosis of prostate cancer annually, as per Prostate Cancer UK.

Unlock Affordable Relief! ?? Explore Low-Cost Knee Osteoarthritis Stem Cell Treatment in India. Break Free from Pain, Embrace Mobility. Your Path to Wellness Starts Now!

In our quest for perfect skin, the landscape of dermatology and skin care has evolved dramatically, offering breakthrough treatments and solutions. The pursuit of a blemish-free, radiant complexion is no longer a distant dream, thanks to advancements in medical aesthetics and skincare technology. From non-invasive procedures to tailor-made skincare regimens, individuals now have access to a plethora of options designed to target specific skin concerns. This article explores the cutting-edge treatments that promise to diminish imperfections and reveal flawless skin, transforming not just how we look but also how we feel about ourselves. Botox Injections Botox, or Botulinum toxin, has gained immense popularity for its ability to smooth out wrinkles and fine lines. It works by temporarily paralyzing the facial muscles responsible for creating these imperfections. The procedure involves injecting small amounts of the neurotoxin into targeted areas, such as the forehead, crow's feet, and frown lines between the brows. The effects of Botox typically last for three to four months, making it a popular choice for those seeking quick and noticeable results. The people at sdbotox.com note that it is also a popular preventative treatment for those looking to delay the formation of wrinkles. With consistent use, Botox can actually prevent fine lines and wrinkles from appearing in the first place, making it an attractive option for individuals in their late 20s and early 30s.

Aspire Pharma Limited, a leading UK provider of niche generic and branded medicines, on Monday, announced that it has successfully acquired Cenoté Pharma as part of the company's ongoing strategy to supplement its organic growth through acquisitions and strategic partnerships. Cenoté Pharma is a UK-based pharmaceutical company that specialises in addressing carnitine deficiencies. Carnitine is an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the liver, heart and muscles. While the exact prevalence of systemic primary carnitine deficiency (SPCD) remains uncertain and varies depending on ethnicity, the estimated prevalence is 1 in 20,000 to 1 in 70,000 newborns in Europe and the USA, as stated by Aspire Pharma in its press release. Aspire CEO Richard Condon expressed enthusiasm about the addition of a new therapy area into the company's portfolio. "This acquisition underscores our commitment to advancing the science and treatment options for vulnerable patient groups," he said.

LloydsPharmacy Clinical Homecare, a leading provider of home healthcare services in the UK, on Monday announced the appointment of Paul Adams as the company's new Chief Executive Officer (CEO). Before assuming his role at LPCH at the end of last year, Adams was leading transformation efforts at DD Group, formerly known as Dental Directory. With a career spanning over two decades, Adams has held influential positions at Diageo, Smith+Nephew, and served as a CEO for various Private Equity companies. He has also co-authored "The Little Black Book of Change." Adams will lead the LPCH's mission to pioneer the delivery of specialist clinical treatment therapies to patients, thereby enhancing patient outcomes within homecare and community settings while improving accessibility.

Veoza, a non-hormonal treatment for menopause, has been made available on the high street for the first time in the UK. British pharmacy chain Superdrug on Thursday (1st February) announced the launch of the newly approved menopause medication, expanding its comprehensive portfolio of products and services to support menopausal women. Veoza is a prescription medication that is used to manage vasomotor symptoms, specifically hot flushes and night sweats, which affect up to 80 per cent of women during menopause, as estimated by experts. It is recommended for women who prefer not to or are unable to take hormone replacement. Perimenopausal, menopausal and postmenopausal women, aged 45-65 who are not on Hormone Replacement Therapy (HRT) or hormonal contraception, and are suffering from moderate to severe vasomotor symptoms, are eligible to take the medication, the retailer said in a release.

Period problems, women's health research and support for domestic and sexual abuse victims are among the government's priorities for women's health in 2024, which Health Secretary Victoria Atkins announced at the Women's Health Summit on Wednesday. Organised in central London, the event marked the second year of the landmark Women's Health Strategy for England. Victoria joined women's health champions to celebrate successes of strategy's first year and outlined plans for coming year, which also include improving maternity care and support for mothers who suffer birth trauma. Successes achieved over the strategy's first 12 months include reducing the cost of hormone replacement therapy (HRT) for nearly half a million women and the rollout of specialist women's health hubs in every local health area. A new dedicated women's health section of the NHS website was also created, providing updated information, advice and practical resources for women's health across the life course.

Many people with advanced Parkinson's disease are currently required to take more than 20 pills a day to manage their symptoms, while some necessitate treatment through a permanent feeding tube. Soon, patients will only be required to wear a portable kit to get a continuous dose of the medication delivered into their bloodstream 24 hours a day. This innovative treatment, called Produodopa, will now be made available on the NHS, providing benefit to nearly 1,000 people with advanced Parkinson's disease, according to a BBC report. James Palmer, NHS England's medical director for specialised services, told the publication that the drug's rollout will offer "a vital new option on the NHS for those who aren't suitable for other treatments such as deep brain stimulation." He added that the new therapy will help patients manage their symptoms "more effectively" and improve their quality of life.

Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.

Nigerian patients often choose India for stem cell treatment due to its renowned medical expertise, advanced technology, and cost-effective healthcare options.

Psoriasis vs Eczema, while both causing itchy, inflamed skin, are distinct conditions with different underlying causes and treatments. Understanding these differences is crucial for proper diagnosis and management. Symptoms: Psoriasis: Thick, red, scaly patches: Often on elbows, knees, scalp, but can affect any area. Silvery scales: Easily removed, revealing inflamed skin beneath. Eczema: Dry, itchy, red patches: Often on inner elbows, knees, hands, face, but can be widespread. Fine, scaling: Less prominent compared to psoriasis. Causes: Psoriasis: Autoimmune condition: Immune system mistakenly attacks healthy skin cells, causing rapid growth and buildup. Genetic predisposition: Family history increases risk. Eczema: Atopic dermatitis: Combination of genetic and environmental factors. Dry skin: Major contributing factor. Treatments: Psoriasis: Topical medications: Steroids, retinoids, vitamin D analogues to reduce inflammation and cell growth. Light therapy: Ultraviolet light exposure to slow skin cell production. Eczema: Moisturizers: Regular use hydrates and protects the skin barrier. Emollients: Oil-based creams to soothe dryness and itching. Key Differences: Cause: Psoriasis is autoimmune, while eczema is complex and involves both genetics and environment. Symptoms: Psoriasis typically has thicker scales and less itching, while eczema is drier and itchier.

More than 500,000 women in England have benefitted from cheaper hormone replacement therapy (HRT) since the launch of the HRT prescription prepayment certificates (PPC) on 1 April last year, according to the Department of Health and Social Care (DHSC). HRT is the main treatment for negative menopause symptoms that can impact all areas of a woman's life. Introduced as part of the government's Women's Health Strategy, which made menopause a priority area, the HRT PPC reduced prescription costs to just £19.30 per year, helping patients save hundreds of pounds in prescription charges. The DHSC has confirmed that more than £11 million was saved by women using the PPC in the last nine months. Using the HRT PPC, patients can get a range of HRT items, including patches, tablets, and topical preparations at reduced prices, and they can use it many times as needed throughout the year.

Welcome to our comprehensive guide on understanding and managing musculoskeletal pain. This type of discomfort, often arising from an injury to the body's muscles, joints, tendons, ligaments, or nerves, can lead to significant functional impairment and reduced quality of life. In the following sections, we'll delve into the causes, diagnosis, and various treatment options for musculoskeletal pain, equipping you with the knowledge you need to manage and alleviate your symptoms effectively. Consult a Medical Professional While this guide offers a general understanding of musculoskeletal pain, it is critical to consult with a healthcare professional for any pain or discomfort you may be experiencing. Health practitioners can offer a proper diagnosis and develop a personalized treatment plan that considers your specific symptoms, condition, and overall health. For example, the best physical therapists can suggest a variety of exercises and stretches to help strengthen muscles and alleviate pain. Some pain may require surgery, while others can be managed with medication or physical therapy. Your medical provider will work with you to find the most effective treatment plan.

Kanabo Group plc, a medical cannabis research and development company, has entered into a partnership with City Dock Pharmacy in London to introduce a walk-in clinic for pain management. The pain clinic will cater to patients who are eligible for alternative therapies (when traditional treatments have failed to deliver improvements), and will offer specialised medicines, including medicinal cannabis. When it opens, the new facility at City Dock Pharmacy in Wapping will become the UK's first walk-in clinic for pain management, but it will also deliver appointment-related services, the companies said. The partnership is part of the London-based company's wider ambition to extend its reach into physical pharmacies throughout the UK, and its plans to replicate this model across other pharmacies.

Renew Hope!

The Department of Health and Social Care (DHSC) has issued an alert to update healthcare professionals on the shortage of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are used to treat type 2 diabetes. It has informed that the supply of the drugs continues to be limited, and is not expected to return to normal until at least the end of 2024. An increase in demand for these products for licensed and off-label indications is cited as the cause of the supply issues. "Rybelsus® (semaglutide) tablets are now available in sufficient quantities to support initiation of GLP1 RA treatment in people with type 2 diabetes (T2DM) in whom new initiation of GLP-1 RA therapy would be clinically appropriate," the DHSC's National Patient Safety Alert reads.

Le coût de la thérapie par cellules souches en Inde, entre 5 lakhs et 8 lakhs, est un élément principal qui fournit une nouvelle lueur d'espoir aux patients du monde entier, car les services cliniques de première classe fournis par les hôpitaux sont à la hauteur.

Proprietary Association of Great Britain, PAGB - which represents manufacturers of branded over-the-counter (OTC) medicines, self-care medical devices and food supplements - on Tuesday (12 December) celebrated 40 years of reclassification of medicines. Expanding self-care for common ailments and minor injuries will not only help ease pressure on primary care services, but also provides significant potential savings for the NHS, the consumer healthcare association highlighted during the event. Nurofen (ibuprofen) and Imodium (loperamide) were the first medicines to go through Medicines and Healthcare products Regulatory Agency (MHRA)'s switch process in 1983 to make them available over the counter - OTC. Other reclassified medicines which were once available on prescription only include Voltarol (diclofenac dimethylammonium), Canesten (clotrimazole), Nexium (esomeprazole), Nicorette, Nicotinell and Niquitin (nicotine replacement therapies), Regaine (minoxidil), Viagra Connect (sildenafil), Cialis Together (tadalafil) for erectile dysfunction and Gina (estradiol hemihydrate) for the treatment of postmenopausal symptoms such as vaginal dryness.